-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NgfC+uNbfG+dv5iweNlh4v1J+U2FRxOE85iBCBVvGOEOT+u717Shbh7d0B726PEz
 NQviVQqwlFxdPlZ8vj+ksw==

<SEC-DOCUMENT>0001005477-07-001625.txt : 20070222
<SEC-HEADER>0001005477-07-001625.hdr.sgml : 20070222
<ACCEPTANCE-DATETIME>20070222163529
ACCESSION NUMBER:		0001005477-07-001625
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20070220
FILED AS OF DATE:		20070222
DATE AS OF CHANGE:		20070222

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Molecular Insight Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001340752
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043412465
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		160 SECOND STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-492-5554

	MAIL ADDRESS:	
		STREET 1:		160 SECOND STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			FEINBERG STEPHEN
		CENTRAL INDEX KEY:			0000947822
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33284
		FILM NUMBER:		07642666

	BUSINESS ADDRESS:	
		BUSINESS PHONE:		2128912120

	MAIL ADDRESS:	
		STREET 1:		299 PARK AVENUE
		STREET 2:		22ND FL
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10171
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>edgar123.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0202</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2007-02-20</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001340752</issuerCik>
        <issuerName>Molecular Insight Pharmaceuticals, Inc.</issuerName>
        <issuerTradingSymbol>MIPI</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0000947822</rptOwnerCik>
            <rptOwnerName>FEINBERG STEPHEN</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CERBERUS CAPITAL MANAGEMENT, L.P.</rptOwnerStreet1>
            <rptOwnerStreet2>299 PARK AVENUE - 22ND FLOOR</rptOwnerStreet2>
            <rptOwnerCity>NEW YORK</rptOwnerCity>
            <rptOwnerState>NY</rptOwnerState>
            <rptOwnerZipCode>10171</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock, par value $0.01 per share</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <transactionDate>
                <value>2007-02-20</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>12396</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>12.4676</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>3726102</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                    <footnoteId id="F1"/>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By limited partnership</value>
                    <footnoteId id="F1"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Cerberus Partners, L.P. (&quot;Cerberus Partners&quot;) is the owner of (i) 3,726,102 shares of the common stock of the Molecular Insight Pharmaceuticals, Inc. (the &quot;Company&quot;), par value $0.01 per share (the &quot;Shares&quot;) and (ii) a Common Stock Purchase Warrant (the &quot;2006 Warrant&quot;) to acquire 256,411 Shares.  Stephen Feinberg, through one or more intermediate entities, possesses sole power to vote and direct the disposition of all securities of the Company owned by Cerberus Partners.  Mr. Feinberg's interest in such securities is limited to the extent of his pecuniary interest in Cerberus Partners, if any.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Stephen Feinberg</signatureName>
        <signatureDate>2007-02-21</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----